Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab

阿柏西普 血管抑制剂 医学 贝伐单抗 眼科 视力 黄斑变性 外科 化疗
作者
Hyung Cho,Chirag P. Shah,Marissa L. Weber,Jeffrey S. Heier
出处
期刊:British Journal of Ophthalmology [BMJ]
卷期号:97 (8): 1032-1035 被引量:170
标识
DOI:10.1136/bjophthalmol-2013-303344
摘要

OBJECTIVE: To investigate the effect of aflibercept 2.0 mg in cases resistant to ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment. PURPOSE: To evaluate the anatomic and visual effect of intravitreal aflibercept 2.0 mg in cases of exudative age-related macular degeneration (AMD) with persistent fluid on optical coherence tomography (OCT) despite regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment at 1 and 6 months. METHODS: Retrospective review at Ophthalmic Consultants of Boston, Boston, Massachusetts, USA of exudative AMD cases with persistent fluid on regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment switched to intravitreal aflibercept 2.0 mg treatment and followed for 6 months. Tabulated data included details of prior treatments, best available visual acuity, central subfoveal thickness on registered spectral domain OCT before and after aflibercept injection centred on the anatomic fovea and macular description before and after aflibercept injection. RESULTS: A total of 353 eyes with exudative AMD were switched to aflibercept during the study period. Of these, 28 eyes in 28 patients had persistent fluid after an average of 20 regular ranibizumab/bevacizumab injections (range 7-37). At 1 month, 89% (25 eyes) showed anatomic improvement and 18% (five eyes) were dry after a single aflibercept injection. Central subfoveal thickness improved from 295 to 272 microns (p<0.001) after one aflibercept injection. After an average of 4.4 aflibercept injections (range 3-6) over 6 months, the central subfoveal thickness remained improved (274 microns, p=0.008); 64% (18 eyes) showed anatomic improvement and a quarter of eyes (25%, seven eyes) were dry. Visual acuity did not improve at 1 month (logarithm of minimum angle of resolution (logMAR) 0.54, Snellen 20/69, p=0.64) or 6 months (logMAR 0.57, Snellen 20/76, p=0.49). Treatment was well tolerated with no adverse events reported. CONCLUSIONS: A significant proportion of exudative AMD cases with persistent fluid on OCT despite regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment respond anatomically to aflibercept 2.0 mg. Visual acuity did not improve. Aflibercept may be beneficial anatomically in cases of exudative AMD treated with persistent fluid on ranibizumab and/or bevacizumab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HALO完成签到,获得积分10
刚刚
刚刚
快乐十一完成签到,获得积分10
1秒前
一二完成签到,获得积分10
1秒前
陶汪酱完成签到,获得积分10
1秒前
曜骅完成签到,获得积分10
2秒前
李萌完成签到,获得积分10
2秒前
深情安青的应助被Afterlife34采纳,获得10
3秒前
wfy完成签到,获得积分10
3秒前
3秒前
4秒前
大个的应助被小小的飞机采纳,获得10
4秒前
4秒前
搞怪的老九完成签到,获得积分0
4秒前
titijaychou发布了新的文献求助10
4秒前
5秒前
5秒前
5秒前
JuPP完成签到,获得积分10
5秒前
易昭华完成签到,获得积分10
5秒前
leotao发布了新的文献求助10
5秒前
5秒前
haoyun完成签到,获得积分10
6秒前
1111完成签到,获得积分10
6秒前
七星嘿咻完成签到,获得积分0
6秒前
科研通AI6.4的应助被尹丹采纳,获得10
6秒前
minminzi完成签到,获得积分10
6秒前
6秒前
7秒前
雪白的白桃完成签到,获得积分10
7秒前
bkagyin的应助被李晓彤采纳,获得10
7秒前
后来吧没事了完成签到,获得积分10
7秒前
8秒前
PPPP发布了新的文献求助10
8秒前
11完成签到,获得积分10
10秒前
失物爱发布了新的文献求助10
10秒前
便便民工发布了新的文献求助10
10秒前
eF完成签到,获得积分10
10秒前
10秒前
cookie完成签到,获得积分20
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570437
关于积分的说明 21812406
捐赠科研通 7776516
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557516
邀请新用户注册赠送积分活动 2479162